Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Kerkhoff

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL TrialConrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Blood|April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL TrialAnne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2026
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysisSophie Wollnitza, David Ventura, Marcel Teichert, et al.
Cancers|August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective AnalysisEvgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL TrialConrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Blood|April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL TrialAnne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2026
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysisSophie Wollnitza, David Ventura, Marcel Teichert, et al.
Cancers|August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective AnalysisEvgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Pageof 5